244
Views
7
CrossRef citations to date
0
Altmetric
Original Articles

Therapy strategy in tumour cells and immune system interaction mathematical model

&
Pages 1548-1559 | Received 01 Oct 2015, Accepted 09 Feb 2016, Published online: 01 Mar 2016

References

  • Stepanova NV. Course of the immune reaction during the development of a malignant tumour. Biophysics. 1980;24:917–923.
  • Martin RB, Fisher ME, Minchin RF, et al. A mathematical model of cancer chemotherapy with an optimal selection of parametrs. Math. Biosci. 1990;99:205–230.
  • de Vladar HP, Gonzalez JA. Dynamic response of cancer under the influence of immunological activity and therapy. J. Theor. Biol. 2004;227:335–348.
  • d’Onofrio A, Ledzewicz U, Maurer H, et al. On optimal delivery of combination therapy for tumors. Math. Biosci. 2009;222:13–30.
  • Kuznetsov V, Makalkin I, Taylor M, et al. Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. B. Math. Biol. 1994;56:295–321.
  • Frascoli F, Kim PS, Hughes BD, et al. A dynamical model of tumour immunotherapy. Math. Biosci. 2014;253:50–62.
  • Roesch K, Hasenclever D, Scholz M. Modeling lymphoma therapy and outcome. Bull. Math. Biol. 2014;76:401–430.
  • Kirschner P, Panetta JC. Modeling immunotherapy of the tumor--immune interaction. J. Math. Biol. 1998;37:235–252.
  • Wilson S, Levy D. A mathematical model of the enhancement of tumor vaccine efficacy by immunotherapy. Bull. Math. Biol. 2012;74:1485–1500.
  • Castiglione F, Piccoli B. Cancer immunotherapy, mathematical modeling and optimal control. J. Theor. Biol. 2007;247:723–732.
  • de Pillis LG, Gallegos A, Radunskaya AE. A model of dendritic cell therapy for melanoma. Front. Oncol. 2013;3:56–77.
  • Itik M, Salamci MU, Banks SP. Optimal control of drug therapy in cancer treatment. Nonlinear Anal. 2009;71:1473–1486.
  • Ledzewicz U, Mosalman MSF, Schaettler H. Optimal controls for a mathematical model of tumor--immune interactions under targeted chemotherapy with immune boost. Discrete Cont. Dyn. -B. 2013;18:1031–1051.
  • Martin RB. Optimal control drug scheduling of cancer chemotherapy. Automatica. 1992;28:205–230.
  • de Pillis LG, Fister KR, Gu W, et al. Seeking bang--bang solutions of mixed immuno-chemotherapy of tumors. Electr. J. Differ. Equ. 2007;2007:1–24.
  • de Pillis LG, Fister KR, Gu W, et al. Optimal control of mixed immunotherapy and chemotherapy of tumors. J. Biol. Syst. 2008;16:841–862.
  • de Pillis LG, Fister KR, Gu W, et al. Mathematical model creation for cancer chemo-immunotherapy. Comput. Math. Method M. 2009;10:165–184.
  • de Pillis LG, Gu W, Radunskaya AE. Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations. J. Theor. Biol. 2006;238:841–862.
  • Matveev AS, Savkin AV. Application of optimal control theory to analysis of cancer chemotherapy regimens. Syst. Control Lett. 2002;46:311–321.
  • Bratus AS, Fimmel E, Todorov Y, et al. On strategies on a mathematical model for leukemia therapy. Nonlinear Anal.-Real. 2012;13:1044–1059.
  • Engelhart M, Lebiedz D, Sager S. Optimal control for selected cancer chemotherapy ODE models: a view on the potential of optimal schedules and choice of objective function. Math. Biosci. 2011;229:123–134.
  • Pontryagin LS, Boltyanski VG, Gamkrelidze RV, et al. The mathematical theory of optimal processes. Moscow: Nauka; 1969.
  • Moiseev NN. Computational methods in the theory of optimal systems. Moscow: Nauka; 1971.
  • Vasiliev FP. Methods of optimization. Moscow: Factorial Press; 2002.
  • Krylov IA, Chernousko FI. Algorithm of successive approximations for problems of optimal control. J. Comp. Math. Math. Phys. 1972;12:14–34.
  • Srochko VA. Iteration methods for the solution of optimal control problems. Moscow: Fizmatlit; 2000.
  • Dienfenbach A, Jensen ER, Jamieson AM, et al. Rae1 and H60 ligands of the NKG2D receptor stimulate tumor immunity. Nature. 2001;413:165–171.
  • Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850–854.
  • Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol. 2010;7:455–465.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.